← Back
Data updated: Jun 28, 2026
PERRIGO NEW YORK
Generics Pharmaceuticals
PERRIGO NEW YORK is a generic drug manufacturer with 10 FDA-approved products.
1986
Since
10
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
PERRIGO NEW YORK's Key Drugs
PERRIGO NEW YORK's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
No active drugs
PERRIGO NEW YORK's Recent FDA Approvals
New NDA/BLA approvals for PERRIGO NEW YORK over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
PERRIGO NEW YORK's Therapeutic Areas
Disease areas where PERRIGO NEW YORK has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
PERRIGO NEW YORK Pipeline Snapshot
Active clinical trials for PERRIGO NEW YORK across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1986-12-01
- Latest
- 2015-09-24
- Applications
- 22